Presented By Alan Venook at 2016 ASCO Annual Meeting

Slides:

Advertisements

Similar presentations

Synopsis of FDA Colorectal Cancer Endpoints Workshop Michael J. O’Connell, MD Director, Allegheny Cancer Center Associate Chairman, NSABP Pittsburgh, PA.

Advertisements

Cáncer de Colon: Resultados de los estudios CRYSTAL, FIRE3 y CALGB Andrés Cervantes.

Introduction Patients and Methods Results Conclusion Wnt signaling is essential for embryonic development, stem cells and tissue regeneration. Colorectal.

Presented By Raymond Huang at 2014 ASCO Annual Meeting

CALGB/SWOG 80405: Phase III trial of FOLFIRI or FOLFOX with Bevacizumab or Cetuximab for patients w/ KRAS wild type untreated metastatic adenocarcinoma.

Post G.I. ASCO Update: Colorectal Cancer Ronald Burkes, M.D.

Adjuvant Therapy of Colon Cancer 2005 Daniel G. Haller, M.D. Abramson Cancer Center at the University of Pennsylvania Philadelphia PA.

*University Hospital Gasthuisberg, Leuven, Belgium

Impact of age and comorbidities on treatment effect, tolerance and toxicity in metastatic colorectal cancer (mCRC) patients (pts) treated on CALGB

Bevacizumab may Differentially Improve Survival for Patients with the Proliferative and Mesenchymal Molecular Subtype of Ovarian Cancer Presented By Boris.

Colorectal Cancer Abstracts Oral Session: 6/6/10 Alan P. Venook, M.D. University of California, San Francisco.

Presented By Fortunato Ciardiello at 2014 ASCO Annual Meeting

Cetuximab plus FOLFIRI in the treatment of metastatic colorectal cancer: the influence of KRAS and BRAF biomarkers on outcome: updated data from the CRYSTAL.

Monoclonal Antibodies EGFR Inhibitors for Metastatic Colorectal Cancer: Where are we and What’s next Discussion of Abstracts Jeffrey Meyerhardt,

Who can benefit from chemotherapy holidays after first-line therapy for advanced colorectal cancer ? N. Perez-Staub, B. Chibaudel, A. Figer, A. Cervantes,

Phase III study of first-line XELOX plus bevacizumab (BEV) for 6 cycles followed by CapeOX plus BEV or single agent (s/a) BEV.

Slide 1 Presented By Christian Hinrichs at 2014 ASCO Annual Meeting.

Slide 1 Presented By Jan Buckner at 2014 ASCO Annual Meeting.

Presented By Michael Overman at 2016 ASCO Annual Meeting

Dr. Marco Matos JOURNAL CLUB GCUH 4/07/14.

Presented By Shin Fujita at 2016 ASCO Annual Meeting

Phase III Clinical Trial of FOLFOX with or without Cetuximab in Resected Stage 3 Colon Cancer: Cooperative Group Trial N0147 (NCCTG*,

First line treatment for metastatic colorectal cancer

Higher Vitamin D Levels Associated With Improved Survival in Metastatic Colorectal Cancer CCO Independent Conference Highlights of the 2015 ASCO Annual.

CCO Independent Conference Highlights

CCO Independent Conference Coverage

Prognostic Factors for First-line Chemotherapy + Bevacizumab or Cetuximab in Metastatic Colorectal Cancer CCO Independent Conference Highlights* of the.

Combination chemotherapy with bevacizumab and S-1 for elderly patients with metastatic colorectal cancer (BASIC trial) M. Yoshida, K. Muro, A. Tsuji,

Fig. 3 Overall and disease-free survival of single-zone metastasis group according to the number of stations involved. No significant differences were.

Presented By Michael Lee at 2016 ASCO Annual Meeting

Maintenance Lapatinib After Chemotherapy in HER1/2-Positive Metastatic Bladder Cancer CCO Independent Conference Highlights of the 2015 ASCO Annual Meeting*

Presented By Deborah Schrag at 2016 ASCO Annual Meeting

Figure 1. (A) Forest plot of common odds ratios (adjusted for ECOG PS) for best overall response by a priori subgroups in patients with KRAS wild-type.

Presented By Luca Malorni at 2017 ASCO Annual Meeting

Fondazione Poliambulanza - Brescia

Trifluridine/Tipiracil (TAS-102) Improves Survival in Patients With Metastatic CRC and Mild Renal/Hepatic Impairment: Subgroup Analysis of RECOURSE CCO.

CLINICAL AND BUDGET IMPACT OF USING A MOLECULAR TEST TO DETECT KRAS MUTATIONS IN METASTATIC COLORECTAL CANCER PATIENTS IN THE UNITED STATES Cheng I1, Hertz.

Introduction. TREATMENT BASED ON TUMOR SIDEDNESS IN mCRC: THE EVIDENCE AND PRACTICAL APPLICATION.

BRAF mutant mCRC patients – What would you recommend? FOLFIRINOX/Bev

Challenges in RAS Wild-Type mCRC

New ESMO Guidance on Tumor Sidedness in mCRC

A Paradigm Shift From One-Size-Fits-All to Tailor-Made Therapy for Metastatic Colorectal Cancer.

What to Do Next: Sequencing of Therapy in Patients With Metastatic CRC

Introduction. TREATMENT BASED ON TUMOR SIDEDNESS IN mCRC: THE EVIDENCE AND PRACTICAL APPLICATION.

Axel Grothey Professor of Oncology Mayo Clinic Rochester

Alan P. Venook, MD University of California, SF

Colorectal Cancer: Current “Standard” Uses for Molecular Testing

Genetic variants of kinases suppressors of Ras (KSR)in KRAS-BRAF

Presented By Johanna Bendell at 2016 ASCO Annual Meeting

A subgroup analysis of a large multicenter study

Table 2. Progression-Free Survival

Treatment Outcomes by Tumor Histology in Eastern Cooperative Group Study E4599 of Bevacizumab with Paclitaxel/Carboplatin for Advanced Non-small Cell.

ERCC1 and BRAC1 mRNA Expression Levels in the Primary Tumor Could Predict the Effectiveness of the Second-Line Cisplatin-Based Chemotherapy in Pretreated.

Published online September 20, 2017 by JAMA Surgery

Algorithms for the management of metastatic colorectal cancer: (A) resectable metastatic disease; (B) metastatic disease, first-line; (C) metastatic disease,

The Prognostic Impact of KRAS, Its Codon and Amino Acid Specific Mutations, on Survival in Resected Stage I Lung Adenocarcinoma Benjamin Izar, MD, PhD,

Cetuximab with chemotherapy as 1st-line treatment for metastatic colorectal cancer: a meta-analysis of the CRYSTAL and OPUS studies according to KRAS.

Primary side of origin affects the outcome of mCRC patients treated with first-line FOLFIRI plus bevacizumab independently of BRAF status and mucinous.

Raymond N. DuBois, M.D., Ph.D. Executive Director

Ali Shamseddine,MD,FRCP

Phase III study of irinotecan/5FU/LV (FOLFIRI) or oxaliplatin/5FU/LV (FOLFOX) +/- cetuximab for patients with untreated metastatic adenocarcinoma of the.

KRAS Mutations in Advanced Nonsquamous Non–Small-Cell Lung Cancer Patients Treated with First-Line Platinum-Based Chemotherapy Have No Predictive Value

Presented By Caroline Dartigeas at 2016 ASCO Annual Meeting

Plasma Levels Correlate with Clinical Benefit

Impact of Tumor Size on Local Control and Pneumonitis After Stereotactic Body Radiation Therapy for Lung Tumors Sean M. Parker, BS, R. Alfredo Siochi,

Kaplan-Meier curves for PFS (panel A) and OS (panel B) of patients with mTCC receiving an anti-EGFR based therapy. mTCC, metastatic transverse colon cancer;

Treatment Outcomes by Tumor Histology in Eastern Cooperative Group Study E4599 of Bevacizumab with Paclitaxel/Carboplatin for Advanced Non-small Cell.

Schema of the exploratory analyses (RAS wild-type population)

Kaplan-Meier analysis of overall survival in patients receiving panitumumab→VEGFi (PEAK and PRIME) versus bevacizumab→EGFRi (PEAK and 181) in the (A) RAS.

STK11/LKB1 genetic alterations are associated with shorter progression-free and overall survival with PD-1 blockade among KRAS-mutant LUAC in the SU2C.

Presentation transcript:

Presented By Alan Venook at 2016 ASCO Annual Meeting Impact of primary tumor location on<br /> Overall Survival and Progression Free Survival <br />in patients with metastatic colorectal cancer: <br /> Analysis of CALGB/SWOG 80405 (Alliance) Presented By Alan Venook at 2016 ASCO Annual Meeting

Presented By Alan Venook at 2016 ASCO Annual Meeting CALGB/SWOG 80405 Presented By Alan Venook at 2016 ASCO Annual Meeting

Presented By Alan Venook at 2016 ASCO Annual Meeting CALGB/SWOG 80405 Presented By Alan Venook at 2016 ASCO Annual Meeting

Presented By Alan Venook at 2016 ASCO Annual Meeting Slide 4 Presented By Alan Venook at 2016 ASCO Annual Meeting

Embryology: The origin of the colon Presented By Alan Venook at 2016 ASCO Annual Meeting

Presented By Alan Venook at 2016 ASCO Annual Meeting Slide 6 Presented By Alan Venook at 2016 ASCO Annual Meeting

CALGB 80405: Side of primary tumor<br /> Methods Presented By Alan Venook at 2016 ASCO Annual Meeting

Presented By Alan Venook at 2016 ASCO Annual Meeting Slide 8 Presented By Alan Venook at 2016 ASCO Annual Meeting

Patient Characteristics by Tumor Side, 80405 (KRAS wt) Presented By Alan Venook at 2016 ASCO Annual Meeting

80405: Overall Survival by Sidedness Presented By Alan Venook at 2016 ASCO Annual Meeting

80405: OS by Sidedness (Bevacizumab)<br /> Presented By Alan Venook at 2016 ASCO Annual Meeting

80405: OS by Sidedness (Cetuximab)<br /> Presented By Alan Venook at 2016 ASCO Annual Meeting

Presented By Alan Venook at 2016 ASCO Annual Meeting 80405: Sidedness is Prognostic<br />Progression Free Survival (PFS) Presented By Alan Venook at 2016 ASCO Annual Meeting

80405: Sidedness is Prognostic<br /> Overall Survival (OS) Presented By Alan Venook at 2016 ASCO Annual Meeting

Presented By Alan Venook at 2016 ASCO Annual Meeting Slide 15 Presented By Alan Venook at 2016 ASCO Annual Meeting

Median OS by Sidedness:<br />80405 and FIRE-3* Presented By Alan Venook at 2016 ASCO Annual Meeting

Presented By Alan Venook at 2016 ASCO Annual Meeting 80405: Sidedness Predictive for Biologics <br /> Biologic by 1° Side Interaction Presented By Alan Venook at 2016 ASCO Annual Meeting

Overall Survival by Sidedness and Biologic Presented By Alan Venook at 2016 ASCO Annual Meeting

OS by Biologic<br /> Right-sided primary Presented By Alan Venook at 2016 ASCO Annual Meeting

OS by Biologic<br />Left-sided primary Presented By Alan Venook at 2016 ASCO Annual Meeting

CALGB/SWOG 80405: <br /> Sidedness in KRAS wt mCRC Presented By Alan Venook at 2016 ASCO Annual Meeting

<br /> Sidedness in mCRC: Biological surrogate Presented By Alan Venook at 2016 ASCO Annual Meeting

Presented By Alan Venook at 2016 ASCO Annual Meeting <br /> Correlative Studies<br /> Tumor / Plasma / Serum > 44000 samples<br /> Presented By Alan Venook at 2016 ASCO Annual Meeting

CALGB/SWOG 80405: Limitations Presented By Alan Venook at 2016 ASCO Annual Meeting

Presented By Alan Venook at 2016 ASCO Annual Meeting 80405: Sidedness Prognostic in KRAS mut patients<br /> (KRAS mutant pts, pre-amendment cohort) Presented By Alan Venook at 2016 ASCO Annual Meeting

80405: Exploratory Analysis (wt v mut )<br /> Presented By Alan Venook at 2016 ASCO Annual Meeting

Sidedness in mCRC: Take Home Messages Presented By Alan Venook at 2016 ASCO Annual Meeting

Stay Tuned: <br /> Next three presentations Presented By Alan Venook at 2016 ASCO Annual Meeting

Presented By Alan Venook at 2016 ASCO Annual Meeting Sidedness in mCRC Presented By Alan Venook at 2016 ASCO Annual Meeting

Presented By Alan Venook at 2016 ASCO Annual Meeting ACKNOWLEDGEMENTS Presented By Alan Venook at 2016 ASCO Annual Meeting

Presented By Alan Venook at 2016 ASCO Annual Meeting THANK YOU Presented By Alan Venook at 2016 ASCO Annual Meeting

Rachel Pearline, MD, MPH<br /> in memorium: 1977 - 2015 Presented By Alan Venook at 2016 ASCO Annual Meeting

Presented By Alan Venook at 2016 ASCO Annual Meeting Slide 33 Presented By Alan Venook at 2016 ASCO Annual Meeting